Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02836613 · ClinicalTrials.gov registry record · Phase 1
A Study of Galcanezumab in Healthy Participants.
A Phase 1 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 1
- Development phase
- 160
- Enrollment target
NCT02836613 is a Phase 1 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 160 participants.
The verdict
NCT02836613, a Phase 1 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 160 participants
- Enrollment target
Study Summary
The main purpose of this study is to evaluate how much galcanezumab gets into the body after it is given as an injection just under the skin by two different devices. This study will measure how much galcanezumab reaches the blood stream and will test how it affects calcitonin-gene related peptide (CGRP) in blood. Information about any side effects that may occur will be collected. The study will last about 20 weeks for each participant. Screening is required within 45 days prior to the start of the study.
Interventions
- BIOLOGICAL Galcanezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2016-07 |
| Est. Completion | 2017-11-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02836613
The ClinicalTrials.gov registry entry for NCT02836613 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Galcanezumab is the first listed.
NCT02836613 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02836613 about?
NCT02836613 is a clinical study titled "A Study of Galcanezumab in Healthy Participants.". The main purpose of this study is to evaluate how much galcanezumab gets into the body after it is given as an injection just under the skin by two different devices. This study will measure how much galcanezumab reaches the blood stream and will test how it affects calcitonin-gene related peptide (...
What is the current status of trial NCT02836613?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 160 participants. The study started on 2016-07. Estimated completion is 2017-11-09.
What interventions are being tested in trial NCT02836613?
The interventions under investigation include: Galcanezumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02836613?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.